Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 8/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120536 | 0.98 | AGER (0.34) | AGERMEN1KMT2AFAAHCYP19A1 | |
| SCHEMBL730322 | 0.82 | — | — | |
| SCHEMBL729770 | 0.82 | MEN1 (0.31) | MEN1 | |
| SCHEMBL732273 | 0.80 | GSK3B (0.35) | MEN1KMT2AMAPT | |
| SCHEMBL5891827 | 0.77 | CYP19A1 (0.36) | CYP19A1MAOB | |
| SCHEMBL729979 | 0.73 | PRSS1 (0.31) | — | |
| SCHEMBL729746 | 0.73 | MEN1 (0.37) | MEN1KMT2AKDM4EMAPTHIF1A | |
| SCHEMBL8156300 | 0.72 | CYP19A1 (0.33) | MEN1CYP19A1 | |
| SCHEMBL8156288 | 0.72 | MAOB (0.39) | MAOB | |
| SCHEMBL2910386 | 0.70 | TOP2A (0.37) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-2007771-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192149-A1 | Imidazo Compounds | CYP19A1, CYP11B2, GPER1 | AGER 3332/4885MEN1 460/4885KMT2A 1116/4885 |
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | AGER 2750/4885MEN1 400/4885KMT2A 3087/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | AGER 2834/4885MEN1 295/4885KMT2A 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.